NCT06711887: Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

Sponsor: Novartis Pharmaceuticals. Phase: PHASE3. Conditions: Lupus Nephritis